|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-3-14
|
|
pubmed:abstractText |
Permanent inactivation of cyclooxygenase-1 and inhibition of platelet thromboxane A(2) (TxA(2)) constitute the main mechanisms underlying the prevention of vascular disease by aspirin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1538-7836
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
615-21
|
|
pubmed:meshHeading |
pubmed-meshheading:18221358-Aged,
pubmed-meshheading:18221358-Aspirin,
pubmed-meshheading:18221358-Blood Platelets,
pubmed-meshheading:18221358-Collagen,
pubmed-meshheading:18221358-Cyclooxygenase 1,
pubmed-meshheading:18221358-Cyclooxygenase Inhibitors,
pubmed-meshheading:18221358-Drug Resistance,
pubmed-meshheading:18221358-Erythrocytes,
pubmed-meshheading:18221358-Female,
pubmed-meshheading:18221358-Humans,
pubmed-meshheading:18221358-Male,
pubmed-meshheading:18221358-Middle Aged,
pubmed-meshheading:18221358-Platelet Activation,
pubmed-meshheading:18221358-Platelet Aggregation,
pubmed-meshheading:18221358-Platelet-Rich Plasma,
pubmed-meshheading:18221358-Serotonin,
pubmed-meshheading:18221358-Thromboxane A2,
pubmed-meshheading:18221358-Vascular Diseases
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease.
|
|
pubmed:affiliation |
Research Center, University Hospital La Fe, Valencia, Spain. santos_ter@gva.es
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
